Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Brausi, Maurizio; Oddens, Jorg; Sylvester, Richard; Bono, Aldo; van de Beek, Cees; van Andel, George; Gontero, Paolo; Turkeri, LEVENT; Marreaud, Sandrine; Collette, Sandra; Oosterlinck, Willem

doi:10.1016/j.eururo.2013.07.021

Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Atıf İçin Kopyala

Brausi M., Oddens J., Sylvester R., Bono A., van de Beek C., van Andel G., ...Daha Fazla

EUROPEAN UROLOGY, cilt.65, sa.1, ss.69-76, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 1
Basım Tarihi: 2014
Doi Numarası: 10.1016/j.eururo.2013.07.021
Dergi Adı: EUROPEAN UROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.69-76
Anahtar Kelimeler: Urothelial carcinoma, Non-muscle-invasive bladder cancer, Maintenance BCG, Dose reduction, Side effects, MITOMYCIN-C, EUROPEAN ORGANIZATION, PRACTICE RECOMMENDATIONS, UROTHELIAL CARCINOMA, FORMAL METAANALYSIS, III TRIAL, 27 MG, PROGRESSION, TOXICITY, TUMORS
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: Although bacillus Calmette-Guerin (BCG) has proven highly effective in non-muscle-invasive bladder cancer (NMIBC), but it can cause severe local and systemic side effects.